- Home
- VGZ vs ACRS Comparison
VGZ vs ACRS Comparison
Compare VGZ & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGZ
- ACRS
- Stock Information
- Founded
- VGZ 1983
- ACRS 2012
- Country
- VGZ United States
- ACRS United States
- Employees
- VGZ N/A
- ACRS N/A
- Industry
- VGZ
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- VGZ
- ACRS Health Care
- Exchange
- VGZ Nasdaq
- ACRS Nasdaq
- Market Cap
- VGZ 143.6M
- ACRS 165.7M
- IPO Year
- VGZ N/A
- ACRS 2015
- Fundamental
- Price
- VGZ $0.98
- ACRS $1.42
- Analyst Decision
- VGZ Strong Buy
- ACRS Strong Buy
- Analyst Count
- VGZ 1
- ACRS 8
- Target Price
- VGZ $2.75
- ACRS $9.71
- AVG Volume (30 Days)
- VGZ 919.5K
- ACRS 1.3M
- Earning Date
- VGZ 07-28-2025
- ACRS 08-06-2025
- Dividend Yield
- VGZ N/A
- ACRS N/A
- EPS Growth
- VGZ N/A
- ACRS N/A
- EPS
- VGZ 0.08
- ACRS N/A
- Revenue
- VGZ N/A
- ACRS $17,777,000.00
- Revenue This Year
- VGZ N/A
- ACRS N/A
- Revenue Next Year
- VGZ N/A
- ACRS $11.77
- P/E Ratio
- VGZ $12.47
- ACRS N/A
- Revenue Growth
- VGZ N/A
- ACRS N/A
- 52 Week Low
- VGZ $0.46
- ACRS $1.05
- 52 Week High
- VGZ $1.30
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- VGZ 45.48
- ACRS 57.34
- Support Level
- VGZ $0.98
- ACRS $1.34
- Resistance Level
- VGZ $1.03
- ACRS $1.66
- Average True Range (ATR)
- VGZ 0.03
- ACRS 0.09
- MACD
- VGZ -0.01
- ACRS 0.01
- Stochastic Oscillator
- VGZ 34.56
- ACRS 69.55
About VGZ Vista Gold Corp
Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects. The company evaluate, acquire, explore and advance gold exploration and potential development projects for gold production or value adding strategic transactions. The Company has one reportable segment: Australia. The Australia segment conducts exploration, development, care and maintenance activities at Vista's asset, the Mt Todd gold project in Northern Territory, Australia.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.